Researchers utilized the comprehensive score for financial toxicity tool to measure self-reported financial distress among 1500-plus patients with cancer or autoimmune diseases receiving charitable copay assistance foundation support.
Medicare has chosen 15 prescription medications for price negotiations this year, building off a first round of negotiations for 10 drugs whose lower prices take effect in 2026. T
The best Medicare plans for cancer patients are a Medigap Plan G from AARP and a Medicare Part D plan from Wellcare. Alternatively, if your cancer diagnosis means you can't qualify for Medigap, choose a Medicare Advantage plan from Aetna. In both cases ...
A new study examining the use of high-cost drugs among patients with colorectal cancer and non-small cell lung cancer found those insured through Medicare Advantage received less expensive cancer drugs compared to others on Traditional Medicare.
WASHINGTON — Medicare officials announced plans to negotiate the prices of blockbuster diabetes and weight loss drugs Ozempic and Wegovy, further complicating big decisions the Trump administration will have to make about how to cover the medications.
Shares of Guardant Health (NASDAQ:GH) have increased by 5.0% in premarket trading Tuesday following the company's announcement that its Guardant Reveal test for colon cancer has been granted expanded Medicare coverage.
The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts before President-elect Trump’s inauguration. The Centers for Medicare
The hugely popular medications Ozempic and Wegovy, used for diabetes and weight loss, will be included in the next round of talks to negotiate lower Medicare drug prices.
Cancer treatment costs about $150,000 per patient. In 2015, spending for cancer treatment and care in the United States was estimated at $183 billion | Cancer
Cancer treatment access differs significantly between traditional Medicare and Medicare Advantage (MA), according to new research from the University of Colorado Cancer Center.
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.
Guardant Health has secured Medicare coverage from Palmetto for its blood test to monitor for disease recurrence in patients with colorectal cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback